Latest appointment boosts LEO Pharma’s translational medicine focus

Boehringer Ingelheim acquires AMAL Therapeutics

LEO Pharma, the Danish dermatology specialist, has appointed Thomas Hultsch as Head of Translational Medicine.

Mr Hultsch will be tasked with building LEO Pharma’s foothold in Translational Medicine across the US and Europe.

He will also lead the establishment of a new Translational Medicine group in Boston.

This latest appointment follows the addition of Adam B. Raff as Director and Medical Advisor in Translational Medicine earlier this month.

Kim Kjoeller, Executive Vice President for Global Research and Development at LEO Pharma, said:  “The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that.

“It will strengthen LEO Pharma as a science driven organisation by increasing our level of science and dermatology knowledge and thus enable us to explore cutting edge technologies in patients more rapidly.”

Per Sproegel, Vice President, Medical Science at LEO Pharma, added: “Thomas Hultsch comes to LEO Pharma with an extensive network within immune dermatology in the US and Europe as well as an impressive track record of initiating successful scientific collaborations.

“With his appointment as Head of LEO Pharma’s new Translational Medicine Unit in Boston, we are ready to take translational medicine at LEO Pharma to the next level in terms of being a science driven and patient focused company.”